- CLIA Method
- ELISA Method
Prostate-Specific Antigen (PSA) Test Market size was valued at USD 3,276.9 Million in 2022 and is poised to grow at a significant CAGR of 11.5% from 2023-2029. PSA or prostate-specific antigen testing determines the amount of PSA in human blood. The prostate is a tiny gland in a man's reproductive system placed underneath the bladder. Prostate-specific antigen is a glycoprotein released by prostatic epithelial cells, and PSA is either attached to other cells or freely circulates throughout the body. The CLIA method segment is anticipated to grow at a significant CAGR over the forecast years, owing to CLIA solutions being frequently used in identifying chronic diseases such as infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and prostate cancer. CLIA is also utilized for therapeutic medication monitoring by several pharmaceutical corporations and research institutions. Rising awareness of the need for early detection of chronic diseases and increased medication discovery and development operations by pharmaceutical firms are viewed as high-impact key drivers for the Segment. Increase in prostate cancer among men, who are over 50 years of age. Furthermore, the adoption of various assay-based methods and various new inventions for the diagnosis of prostate cancer has raised the demand for industry's growth over the forecasting period.
Prostate-Specific Antigen (PSA) Test Market Key Developments:
- In September 2021: Boston Scientific Corporation, the leading medical device manufacturer, announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC) of the liver.
Prostate Specific Antigen Test Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
11.5%
Largest Market
North American
Fastest Growing Market
Asia-Pacific
Prostate-Specific Antigen (PSA) Test Market Dynamics
The market for prostate-specific antigen testing is expanding due to a rise in the elderly population. Additionally, rising public awareness about the benefits of prostate cancer screening, technological advancements in testing and treating prostate cancer, and various reimbursement policies for prostate cancer treatments in different developed and developing regions are influencing the growth of the prostate-specific antigen market, according to the Census Bureau's 2017 National Population Projections, all baby boomers will be over 65, implying that one in every five people would be of retirement age. This reflects an increase in the geriatric population.
North America Got Significant Share
Prostate-Specific Antigen (PSA) Test Market Regional Analysis
The Prostate-Specific Antigen (PSA) Test market in North America is likely to hold the highest revenue share in 2021, and the same trend is expected over the forecast period due to the ensuing high mortality rate in various developed nations, as well as the growing prevalence of prostate cancer in this area, will drive the expansion of the Prostate Specific Antigen (PSA) Testing Market in the future years. Furthermore, increased government attention to prostate cancer diagnosis and improvement in healthcare is expected to drive the expansion of the region's Prostate Specific Antigen (PSA) Testing Market. Moreover, according to the research study in North America older males and non-Hispanic Black men have a higher risk of developing prostate cancer. It is uncommon in men under 40 and is diagnosed in about 6 out of 10 men who are 65 or older. The typical diagnostic age for men is 66.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Prostate Specific Antigen Test Market Segmentation
By Type
By Application
- Screening
- Post-treatment Monitoring
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The prostate-specific antigen (PSA) test market size was valued at USD 3,276.9 million in 2022
Abbott, Siemens Healthcare, DiaSorino, Roche, Beckman Coulter, Mediwatch (LABORIE), BodiTech-Bristol-Myers Squibb Company, GE Healthcare, Endocare, GlaxoSmithKline, Anixa Biosciences, Ortho Clinicals, Fujirebio, Pharmacia Delfia
The prostate specific antigen test market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Prostate-Specific Antigen (PSA) Test Market Introduction |
| 2.1. Global Prostate-Specific Antigen (PSA) Test Market Taxonomy |
| 2.2. Global Prostate-Specific Antigen (PSA) Test Market Definitions |
| 2.2.1. By Type |
| 2.2.2. By Application |
| 2.2.3. By Region |
| 3. Global Prostate-Specific Antigen (PSA) Test Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Prostate-Specific Antigen (PSA) Test Market Dynamic Factors - Impact Analysis |
| 3.6. Global Prostate-Specific Antigen (PSA) Test Market Competition Landscape |
| 4. Global Prostate-Specific Antigen (PSA) Test Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Prostate-Specific Antigen (PSA) Test Market, By Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. CLIA Method |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. ELISA Method |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Prostate-Specific Antigen (PSA) Test Market, By Application, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Screening |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Post-treatment Monitoring |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Prostate-Specific Antigen (PSA) Test Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Prostate-Specific Antigen (PSA) Test Market - Opportunity Analysis Index, By Type, By Application, and Region, 2024 - 2030 |
| 8. North America Prostate-Specific Antigen (PSA) Test Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. By Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. CLIA Method |
| 8.1.2. ELISA Method |
| 8.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Screening |
| 8.2.2. Post-treatment monitoring |
| 8.2.3. Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Prostate-Specific Antigen (PSA) Test Market - Opportunity Analysis Index, By Type, By Application, and Country, 2024 - 2030 |
| 8.5. North America Prostate-Specific Antigen (PSA) Test Market Dynamics Trends |
| 9. Europe Prostate-Specific Antigen (PSA) Test Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. By Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. CLIA Method |
| 9.1.2. ELISA Method |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Screening |
| 9.2.2. Post-treatment monitoring |
| 9.2.3. Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Rest of Europe |
| 9.4. Europe Prostate-Specific Antigen (PSA) Test Market - Opportunity Analysis Index, By Type, By Application, and Country, 2024 - 2030 |
| 9.5. Europe Prostate-Specific Antigen (PSA) Test Market Dynamics Trends |
| 10. Asia-Pacific Prostate-Specific Antigen (PSA) Test Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. By Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. CLIA Method |
| 10.1.2. ELISA Method |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Screening |
| 10.2.2. Post-treatment monitoring |
| 10.2.3. Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. Japan |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Prostate-Specific Antigen (PSA) Test Market - Opportunity Analysis Index, By Type , By Application, and Country, 2024 - 2030 |
| 10.5. Asia-Pacific Prostate-Specific Antigen (PSA) Test Market Dynamics Trends |
| 11. Latin America Prostate-Specific Antigen (PSA) Test Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. By Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. CLIA Method |
| 11.1.2. ELISA Method |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Screening |
| 11.2.2. Post-treatment monitoring |
| 11.2.3. Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of Latin America |
| 11.4. Latin America Prostate-Specific Antigen (PSA) Test Market - Opportunity Analysis Index, By Type , By Application, and Country, 2024 - 2030 |
| 11.5. Latin America Prostate-Specific Antigen (PSA) Test Market Dynamics Trends |
| 12. Middle East and Africa Prostate-Specific Antigen (PSA) Test Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. By Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. CLIA Method |
| 12.1.2. ELISA Method |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Screening |
| 12.2.2. Post-treatment monitoring |
| 12.2.1. Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Prostate-Specific Antigen (PSA) Test Market - Opportunity Analysis Index, By Type , By Application, and Country, 2024 - 2030 |
| 12.5. MEA Prostate-Specific Antigen (PSA) Test Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Abbott |
| 13.2.2. Siemens Healthcare |
| 13.2.3. DiaSorin |
| 13.2.4. Roche |
| 13.2.5. Beckman Coulter |
| 13.2.6. Mediwatch (LABORIE) |
| 13.2.7. BodiTech |
| 13.2.8. Bristol-Myers Squibb Company |
| 13.2.9. GE Healthcare |
| 13.2.10. Endocare |
| 13.2.11. GlaxoSmithKline |
| 13.2.12. Anixa Biosciences |
| 13.2.13. Ortho Clinicals |
| 13.2.14. Fujirebio |
| 13.2.15. Pharmacia Delfia |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- Abbott
- Siemens Healthcare
- DiaSorin
- Roche
- Beckman Coulter
- Mediwatch (LABORIE)
- BodiTech
- Bristol-Myers Squibb Company
- GE Healthcare
- Endocare
- GlaxoSmithKline
- Anixa Biosciences
- Ortho Clinicals
- Fujirebio
- Pharmacia Delfia